• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用全氟基微泡造影剂——全氟丁烷微泡定义肝脏的对比增强期。

Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles.

机构信息

Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.

出版信息

Ultrasound Med Biol. 2009 Nov;35(11):1819-27. doi: 10.1016/j.ultrasmedbio.2009.05.013. Epub 2009 Aug 27.

DOI:10.1016/j.ultrasmedbio.2009.05.013
PMID:19713032
Abstract

To define the contrast enhancement phases in the liver with perflubutane microbubbles, the liver enhancement time-intensity curves were investigated in 14 healthy volunteers. The agent was injected intravenously as a bolus and the liver was imaged with an ultrasound scanner as long as 4h after the injection. Time-intensity curves from the hepatic artery, the intrahepatic portal vein, the hepatic vein and the parenchyma of the liver were obtained from the liver ultrasound images. The arrival of the agent in the hepatic artery, the portal vein and the hepatic vein were visually distinguishable and the mean arrival times were 19.2, 24.3 and 32.2 s after the injection, respectively. The signal intensity in these vessels increased rapidly after the arrival of the contrast and gradually reverted to baseline after the peak. In contrast, within 5 min after the injection, the intensity in the parenchyma increased and reached a plateau, which persisted for at least 2h. The contrast enhancement phases in the liver with perflubutane microbubbles could be defined as two major phases-a vascular phase, in which the vessels are enhanced between 15 s and 10 min after injection, and a Kupffer phase, in which the parenchyma is enhanced 10 min after injection. The vascular phase is divided into three subphases: the arterial phase (15 to 45 s after injection); the portal phase (45 s to 1 min after injection); and the vasculo-Kupffer phase (1 to 10 min after injection).

摘要

为了确定使用全氟丁烷微泡的肝脏对比增强相,对 14 名健康志愿者进行了肝脏增强时间-强度曲线研究。将药物作为团注静脉内注射,在注射后长达 4 小时内使用超声扫描仪对肝脏进行成像。从肝脏超声图像中获得了来自肝动脉、肝内门静脉、肝静脉和肝脏实质的时间-强度曲线。药物到达肝动脉、门静脉和肝静脉是肉眼可分辨的,平均到达时间分别为注射后 19.2、24.3 和 32.2 秒。这些血管中的信号强度在对比剂到达后迅速增加,并在峰值后逐渐恢复到基线。相比之下,在注射后 5 分钟内,实质内的强度增加并达到平台期,至少持续 2 小时。使用全氟丁烷微泡的肝脏对比增强相可定义为两个主要相:血管相,在注射后 15 秒至 10 分钟之间增强血管,库普弗细胞相,在注射后 10 分钟增强实质。血管相分为三个亚相:动脉相(注射后 15 至 45 秒);门静脉相(注射后 45 秒至 1 分钟);和血管-库普弗细胞相(注射后 1 至 10 分钟)。

相似文献

1
Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles.使用全氟基微泡造影剂——全氟丁烷微泡定义肝脏的对比增强期。
Ultrasound Med Biol. 2009 Nov;35(11):1819-27. doi: 10.1016/j.ultrasmedbio.2009.05.013. Epub 2009 Aug 27.
2
Hepatic transit time analysis using contrast-enhanced ultrasound with BR1: A prospective study comparing patients with liver metastases from colorectal cancer with healthy volunteers.使用含BR1的超声造影剂进行肝转运时间分析:一项比较结直肠癌肝转移患者与健康志愿者的前瞻性研究。
Ultrasound Med Biol. 2009 Sep;35(9):1427-35. doi: 10.1016/j.ultrasmedbio.2009.04.002. Epub 2009 Jun 21.
3
Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography.肝硬化性肝病患者肝脏外周血管系统的血流动力学及形态学变化:一项使用对比增强编码相位反转谐波超声检查的初步研究
World J Gastroenterol. 2005 Oct 28;11(40):6348-53. doi: 10.3748/wjg.v11.i40.6348.
4
Obliteration of gastric varices improves the arrival time of ultrasound contrast agents in hepatic artery and vein.胃静脉曲张的消除可提高超声造影剂到达肝动脉和静脉的时间。
J Gastroenterol Hepatol. 2013 Sep;28(9):1526-31. doi: 10.1111/jgh.12234.
5
Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver.基于微泡的超声造影剂肝实质特异性造影机制:大鼠肝脏的微观研究
Invest Radiol. 2007 Sep;42(9):643-51. doi: 10.1097/RLI.0b013e31805f2682.
6
Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma.对比增强超声应用全氟丁烷微泡造影剂:肝细胞癌的鉴别诊断评估。
AJR Am J Roentgenol. 2011 Feb;196(2):W123-31. doi: 10.2214/AJR.10.4242.
7
MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases.肝脏多层螺旋CT与富血供肝细胞癌:优化肝动脉期和门静脉期团注追踪技术的扫描延迟时间
AJR Am J Roentgenol. 2006 Jul;187(1):W25-32. doi: 10.2214/AJR.04.1878.
8
Assessment of global liver blood flow with quantitative dynamic contrast-enhanced ultrasound.使用定量动态对比增强超声评估肝脏整体血流情况。
J Ultrasound Med. 2011 Mar;30(3):379-85. doi: 10.7863/jum.2011.30.3.379.
9
MDCT of the pancreas: optimizing scanning delay with a bolus-tracking technique for pancreatic, peripancreatic vascular, and hepatic contrast enhancement.胰腺的多层螺旋CT:采用团注追踪技术优化扫描延迟以实现胰腺、胰腺周围血管及肝脏的对比增强
AJR Am J Roentgenol. 2007 Mar;188(3):751-6. doi: 10.2214/AJR.06.0372.
10
Hepatic filling rate of a microbubble agent: a novel predictor of long-term outcomes in patients with cirrhosis.微泡剂的肝脏灌注率:肝硬化患者长期预后的一种新预测指标。
Ultrasound Med Biol. 2014 Sep;40(9):2082-8. doi: 10.1016/j.ultrasmedbio.2014.04.014. Epub 2014 Jul 10.

引用本文的文献

1
The American College of Radiology contrast-enhanced ultrasound Liver Imaging Reporting and Data System and its modified version in diagnosing hepatocellular carcinoma via Sonazoid: a meta-analysis.美国放射学会对比增强超声肝脏影像报告和数据系统及其改良版本在通过声诺维诊断肝细胞癌中的应用:一项荟萃分析。
Quant Imaging Med Surg. 2024 Jul 1;14(7):4555-4566. doi: 10.21037/qims-23-1459. Epub 2024 Jun 27.
2
The efficacy of modified contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) using Sonazoid in diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.使用声诺维的改良对比增强超声肝脏影像报告和数据系统(CEUS LI-RADS)在肝细胞癌诊断中的疗效:一项系统评价和荟萃分析。
Quant Imaging Med Surg. 2024 Apr 3;14(4):2927-2937. doi: 10.21037/qims-23-1184. Epub 2024 Mar 21.
3
Nomogram based on Sonazoid contrast-enhanced ultrasound to differentiate intrahepatic cholangiocarcinoma and poorly differentiated hepatocellular carcinoma: a prospective multicenter study.基于 SonoVue 超声造影的列线图鉴别诊断肝内胆管细胞癌和低分化肝细胞癌:一项前瞻性多中心研究。
Abdom Radiol (NY). 2023 Oct;48(10):3101-3113. doi: 10.1007/s00261-023-03993-z. Epub 2023 Jul 12.
4
Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline.用于肝细胞癌无创成像诊断的声诺维增强超声检查:特别强调2022年KLCA-NCC指南
Ultrasonography. 2023 Oct;42(4):479-489. doi: 10.14366/usg.23051. Epub 2023 Jun 15.
5
Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology.使用 SonoVue 对比增强超声诊断肝细胞癌:韩国放射学会和韩国腹部放射学会 2023 年指南。
Korean J Radiol. 2023 Jun;24(6):482-497. doi: 10.3348/kjr.2023.0324.
6
Sonazoid™ versus SonoVue for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study.声诺维对比声振造影用于高危人群诊断肝细胞癌的前瞻性、单中心、个体内、非劣效性研究。
Korean J Radiol. 2022 Nov;23(11):1067-1077. doi: 10.3348/kjr.2022.0388. Epub 2022 Sep 30.
7
Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.用于肝细胞癌成像的对比剂:价值与进展
Front Oncol. 2022 Jun 2;12:921667. doi: 10.3389/fonc.2022.921667. eCollection 2022.
8
Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.含氟丁烷增强超声造影的 Kupffer 期成像:提高肝细胞癌的诊断灵敏度。
Eur Radiol. 2022 Dec;32(12):8507-8517. doi: 10.1007/s00330-022-08900-6. Epub 2022 Jun 16.
9
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.日本肝细胞癌的管理:2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
10
Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging.肝细胞癌消融治疗中的影像引导:对比增强超声与融合成像
Front Oncol. 2021 Mar 5;11:593636. doi: 10.3389/fonc.2021.593636. eCollection 2021.